Biomarkers in Neuroendocrine Tumors

  • Marvin Duque Division of Hematology Oncology, Tufts Cancer Center. Boston, MA, USA
  • Irvin M Modlin Department of Surgery, Yale University School of Medicine. New Haven, CT, USA
  • Anumeha Gupta Division of Hematology Oncology, Tufts Cancer Center. Boston, MA, USA
  • Muhammad Wasif Saif Division of Hematology Oncology, Tufts Cancer Center. Boston, MA, USA
Keywords: Biological Markers, Chromogranin A, Eukaryotic Initiation Factor-4E, Genetic Markers, Molecular Targeted Therapy, Neuroendocrine Tumors, Receptor, IGF Type 1, TOR Serine-Threonine Kinases, Vascular Endothelial Growth Factor Receptor-2

Abstract

Neuroendocrine tumors are a heterogeneous group of tumors with cells of neuroendocrine differentiation that arise from diverse anatomic sites with varying morphologic and clinical features. Since the natural history and prognosis varies widely between individual neuroendocrine tumor types, there is a critical need to identify accurate prognostic and predictive biomarkers and markers predictive of therapeutic efficacy. To date, plasma chromogranin-A levels have generally been accepted as the most useful biomarker, despite the fact that there are substantial concerns in sensitivity and discrepancies in measurement techniques. As a consequence, considerable attention has been focused upon the development of novel biomarkers that can be utilized with more clinical efficacy than chromogranin-A. In addition to amplifying the diagnostic/prognostic landscape, the need to calibrate the efficacy of biological targeted therapy has further accelerated the development of molecular biomarkers. At the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, Chou et al. (Abstract #e15151) presented data that chromogranin A levels can be monitored during treatment to predict clinical outcome. Modlin et al. (Abstract #4137), demonstrated a promising novel biomarker, serum multi-transcript molecular signature. Grande et al. (Abstract #4140), Heetfield et al. (Abstract #e15071) and Casanovas et al. (Abstract #4139) described sVEGFR2, p-mTOR and IGF1R as molecular markers with potential for use in targeted therapy trials. The authors review and summarize these abstracts in this article.

Image: Detail of pipeline used to derive a set of 51 markers that identify GEP-NETs.

Downloads

Download data is not yet available.

Author Biographies

Marvin Duque, Division of Hematology Oncology, Tufts Cancer Center. Boston, MA, USA
Clinical Associate, Department of Medicine, Tufts University School of MedicineFellow, Division of Hematology Oncology, Tufts Medical Center
Irvin M Modlin, Department of Surgery, Yale University School of Medicine. New Haven, CT, USA

Emeritus Professor of Gastroenterological Surgery

Yale University, School of Medicine

Anumeha Gupta, Division of Hematology Oncology, Tufts Cancer Center. Boston, MA, USA

Clinical Associate, Department of Medicine, Tufts University School of Medicine

Fellow, Division of Hematology Oncology, Tufts Medical Center

Muhammad Wasif Saif, Division of Hematology Oncology, Tufts Cancer Center. Boston, MA, USA

Director, GI Oncology Program; Leader, Experimental Therapeutics, Tufts Cancer Center

Assistant Professor of Medicine, Tufts University School of Medicine

References

Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072.

Tsikitis VL, Wetheim BC, Guerrero MA. Trends of incidence and survival o gastrointestinal neuroendocrine tumors in the United States” a SEER analysis. J Cancer 2012;3:292-302.

Modlin IM, Oberg K, Chung DC et al. Gastroenteropatic neuroendocrine tumors. Lancet Oncol 2008; 9:61-72

Lawrence B, Gustafsson BI, Chan A, et. Al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011 40(1):1-18.

Edge SR, Byrd DR, Compton CC et a. Neuroendocrine tumors. AJCC Staging Handbook, 7th edition. 2010.: 227-245.

Klimstra DS, Modlin IM, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39(6):707-12.

Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, Neuron Specific Enolase, Carcinoembryonic Antigen and Hydroxyindole Acetic Acid Evaluation in Patients with Neuroendocrine Tumors. Cancer 1999;86:858-865.

Moran CA, Suster S, Coppola D, et al: Neuroendocrine carcinomas of the lung: A critical analysis. Am J Clin Pathol 131:206- 221, 2009

Yao JC, Lombard-Bohas C, Baudin E, et al: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. J Clin Oncol 28:69-76, 2010.

Kouvaraki MA, Ajani JA, Hoff P, et al. Flourouracil, doxorubicin, and streptozocin in the treatment of patients with advanced and metastatic pancreatic neuroendocrine carcinomas. J Clin Oncol 2004;22:4762-47771.

Belli SH, Oneto A, Aranda C, et al. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina. Acta Gastroenterol Latinoam. 2009 Sep;39(3):184-9.

Kulke M. Sui L, Tepper J et al. Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Tumor Clinical Trials Planning Meeting. J Clin Oncol 2011; 29:934-943.

Modlin IM, Gustafsson BI, Moss SF, et. al. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease.Ann Surg Oncol. 2010;17(9):2427

Zatelli MC, Torta M, Leon A et al. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endoc Relat Cancer 2007; 14:473-482.

AACC (2010) Chromogranin A. Lab Tests Online: American Association for Clinical Chemistry. Pp. Details Regarding Chromogranin A as a test.

NCCN Clinical Practice Guidelines in Oncology/ Neuroendocrine Tumors. Version 2.2013. http://www.nccn.org/ professionas/physician_gls/neuroendocrine.pdf. Accessed June 6, 2013.

Leung R, Lang B, Wong H et al. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy. Anticancer Agents Med Chem 2013;13(3):382-388.

Chou WC and Chang L. Baseline and dynamic plasma chromogranin A (CgA) level to predict clinical outcome and tumor response in Asian patients with gastroenteropancreatic neuroendocrine tumor (GEP-NET). J Clin Oncol 31, 2013 (suppl; abstr #e15151).

Modlin IM, Drozdov I and Kidd, MS. A multi-transcript blood neuroendocrine tumor molecular signature to identify treatment efficacy and disease progress. J Clin Oncol 31, 2013 (suppl; abstr #4137).

Modlin IM, Drozdov I, Kidd M. The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PLoS One. 2013 15;8(5):e63364.

Grande E, Casanovas O, Earl J, et al. sVEGFR2 and circulating tumor cells to predict for the efficacy of pazopanib in neuroendocrine tumors (NETs): PAZONET subgroup analysis. J Clin Oncol 31, 2013 (suppl; #abstr 4140).

Casanovas O, Teule A, Villabona C, et al. Study on activation of the IGF-1R mTOR pathway in neuroendocrine tumours (NETs). J Clin Oncol 31, 2013 (suppl; abstr #4139).

Heetfeld M, Kasajima A, Koch A, et. al. Poorly differentiated neuroendocrine carcinoma (NEC G3): Prognostic factors and potential novel targets. J Clin Oncol 31, 2013 (suppl; abstr #e15071).

Pavel ME, Hainsworth JD, Baudin E, et. al. RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011 10;378(9808):2005-12.

Detail of pipeline used to derive a set of 51 markers that identify GEP-NETs
Published
2013-07-10
How to Cite
Duque, M., Modlin, I., Gupta, A., & Saif, M. (2013). Biomarkers in Neuroendocrine Tumors. JOP. Journal of the Pancreas, 14(4), 372-376. https://doi.org/10.6092/1590-8577/1692
Section
Highlights from the “2013 ASCO Annual Meeting”. Chicago, IL, USA. May 31 - June 4, 2013